<DOC>
	<DOCNO>NCT01703000</DOCNO>
	<brief_summary>NG PROMUS : A Prospective , Multicenter Trial Assess NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System ( NG PROMUS Stent System ) Treatment Atherosclerotic Lesion ( )</brief_summary>
	<brief_title>NG PROMUS Stent System Treatment Atherosclerotic Coronary Lesions</brief_title>
	<detailed_description>To evaluate clinical peri-procedural angiographic intravascular ultrasound ( IVUS ) outcomes NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System ( NG PROMUS Stent System ) treatment subject atherosclerotic lesion ( ) ≤ 34 mm length ( visual estimate ) native coronary artery ≥ 2.50 mm ≤ 4.0 mm diameter ( visual estimate )</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Clinical 1 . Subject must least 18 year age 2 . Subject ( legal guardian ) understand trial requirement treatment procedure provide write informed consent trialspecific test procedure perform 3 . Subject eligible percutaneous coronary intervention ( PCI ) 4 . Subject symptomatic coronary artery disease objective evidence ischemia silent ischemia 5 . Subject acceptable candidate coronary artery bypass grafting ( CABG ) 6 . Subject willing comply protocolrequired followup evaluation Angiographic 1 . Target lesion ( ) must locate native coronary artery visually estimate reference vessel diameter ( RVD ) ≥2.50 mm ≤4.0 mm 2 . Target lesion ( ) length must ≤34 mm ( visual estimate ) 3 . Target lesion ( ) must visually estimate stenosis ≥50 % &lt; 100 % thrombolysis Myocardial Infarction ( TIMI ) flow &gt; 1 one following ( stenosis ≥70 % , abnormal fractional flow reserve ( FFR ) , abnormal stress test imaging stress test , elevate biomarkers ) prior procedure 4 . Coronary anatomy likely allow delivery study device target lesion ( ) 5 . The first lesion treat must successfully predilated/pretreated Note : Successful predilatation/pretreatment refers dilatation balloon catheter appropriate length diameter , pretreatment directional rotational coronary atherectomy , laser cutting/scoring balloon great 50 % residual stenosis dissection great National Heart , Lung , Blood Institute ( NHLBI ) type C. Clinical 1 . Subject clinical symptom and/or electrocardiogram ( ECG ) change consistent acute ST elevation MI ( STEMI ) 2 . Subject cardiogenic shock , hemodynamic instability require inotropic mechanical circulatory support , intractable ventricular arrhythmia , ongoing intractable angina 3 . Subject receive organ transplant wait list organ transplant 4 . Subject receive schedule receive chemotherapy within 30 day index procedure 5 . Planned PCI ( include stag procedure ) CABG index procedure 6 . Subject previously treat time intravascular brachytherapy 7 . Subject know allergy contrast ( adequately premedicated ) and/or trial stent system protocolrequired concomitant medication ( e.g. , platinum , platinumchromium alloy , stainless steel , everolimus structurally related compound , polymer individual component , P2Y12 inhibitor , aspirin ) 8 . Subject one following ( assess prior index procedure ) : Other serious medical illness ( e.g. , cancer , congestive heart failure ) estimate life expectancy le 24 month ; Current problem substance abuse ( e.g. , alcohol , cocaine , heroin , etc . ) ; Planned procedure may cause noncompliance protocol confound data interpretation 9 . Subject receive chronic ( ≥72 hour ) anticoagulation therapy ( i.e. , heparin , coumadin ) indication acute coronary syndrome 10 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 11 . Subject white blood cell ( WBC ) count &lt; 3,000 cells/mm3 12 . Subject document suspected liver disease , include laboratory evidence hepatitis 13 . Subject dialysis baseline serum creatinine level &gt; 2.0 mg/dL ( 177µmol/L ) 14 . Subject history bleed diathesis coagulopathy refuse blood transfusion 15 . Subject history cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within past 6 month 16 . Subject active peptic ulcer active gastrointestinal ( GI ) bleed 17 . Subject sign symptom active heart failure ( i.e. , NYHA class IV ) time index procedure 18 . Subject participate another investigational drug device clinical trial reach primary endpoint 19 . Subject intend participate another investigational drug device clinical trial within 12 month index procedure 20 . Subject know intention procreate within 12 month index procedure ( woman childbearing potential sexually active must agree use reliable method contraception time screen 12 month index procedure ) 21 . Subject woman pregnant nursing ( pregnancy test must perform within 7 day prior index procedure woman childbearing potential ) Angiographic 1 . Planned treatment 3 lesion . 2 . Planned treatment lesion 2 major epicardial vessel 3 . Planned treatment single lesion 1 stent 4 . Subject 2 target lesion vessel separate less 15 mm ( visual estimate ) 5 . Target lesion ( ) locate leave main 6 . Target lesion ( ) locate within 3 mm origin leave anterior descending ( LAD ) coronary artery leave circumflex ( LCx ) coronary artery visual estimate . 7 . Target lesion ( ) locate within saphenous vein graft arterial graft 8 . Target lesion ( ) access via saphenous vein graft arterial graft 9 . Target lesion ( ) TIMI flow 0 ( total occlusion ) TIMI flow 1 prior guide wire cross 10 . Target lesion ( ) treat index procedure involve complex bifurcation ( e.g. , bifurcation lesion require treatment 1 stent ) 11 . Target lesion ( ) restenotic previous stent implantation study stent would overlap previous stent 12 . Subject unprotected leave main coronary artery disease ( &gt; 50 % diameter stenosis ) 13 . Subject treat type PCI ( i.e. , balloon angioplasty , stent , cut balloon atherectomy ) within 24 hour prior index procedure 14 . Thrombus , possible thrombus , present target vessel ( visual estimate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>drug elute coronary stent</keyword>
</DOC>